Viridian Therapeutics, Inc. (VRDN)

Market Cap	1.04B
Revenue (ttm)	302,000
Net Income (ttm)	-243.10M
Shares Out	81.59M
EPS (ttm)	-3.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,045,453
Open	12.24
Previous Close	12.29
Day's Range	11.98 - 13.63
52-Week Range	9.90 - 27.20
Beta	0.62
Analysts	Buy
Price Target	36.82 (+188.11%)
Earnings Date	May 6, 2025

About VRDN

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of e...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: VRDN
• Website: https://www.viridiantherapeutics.com

Financial Performance

In 2024, Viridian Therapeutics's revenue was $302,000, a decrease of -3.82% compared to the previous year's $314,000. Losses were -$208.56 million, 19.2% more than in 2023.

Analyst Forecast

According to 14 analysts, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $36.82, which is an increase of 188.11% from the latest price.

Price Target

$36.82

(188.11% upside)

Analyst Consensus: Buy